Compare ESRT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESRT | GERN |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 907.0M | 808.3M |
| IPO Year | 2012 | N/A |
| Metric | ESRT | GERN |
|---|---|---|
| Price | $5.44 | $1.15 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $6.35 | $2.17 |
| AVG Volume (30 Days) | 2.1M | ★ 11.6M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $768,270,000.00 | N/A |
| Revenue This Year | $4.26 | $26.91 |
| Revenue Next Year | $1.52 | $43.75 |
| P/E Ratio | $540.00 | ★ N/A |
| Revenue Growth | ★ 0.05 | N/A |
| 52 Week Low | $4.87 | $1.04 |
| 52 Week High | $8.76 | $2.01 |
| Indicator | ESRT | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 34.14 |
| Support Level | $5.29 | $1.05 |
| Resistance Level | $5.83 | $1.30 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 31.54 | 27.08 |
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.